GlaxoSmithKline (NYSE:GSK) has had its share of bad press recently — related to a bribery scandal in the company’s Chinese operations — but now the company is giving some good news to adults infected with HIV.
Glaxo’s new daily HIV therapy, Tivicay, has been approved by the Food and Drug Administration. Tivicay has been shown to be more effective than Gilead Science Inc.’s Atripla, which is currently the best-selling HIV drug in the world. Tivicay was developed by ViiV Healthcare Ltd., a joint venture between Glaxo, Pfizer Inc. (NYSE:PFE), and Osaka, Japan-based Shionogi and Co. (SGIOF.PK) Glaxo owns the biggest stake in the venture, with a 76.5 percent share.
“HIV-infected individuals require treatment regimens personalized to fit their condition and their needs,” Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “The approval of new drugs like Tivicay that add to the existing options remains a priority for the FDA.”